MiraVista Diagnostics is an Industry Leading Mycology Reference Laboratory

MiraVista Diagnostics is a CLIA and CAP certified mycology reference laboratory (RL) with an exclusive focus on developing and processing diagnostic tests for serious fungal infections. We offer the highest standards in clinical accuracy and sensitivity for detection, monitoring and diagnostic testing for blastomyces dermatitidis, histoplasma capsulatum, cryptococcus, coccidioides, aspergillus and beta-D glucan.

Clinical Laboratory Testing for Serious Fungal Infections

The company was founded in 2002 by the renowned infectious disease scientist, Dr. Lawrence Joseph Wheat, whose groundbreaking research contributions resulted in the development of the first histoplasmosis antigen test in 1986. Today, MiraVista Diagnostics serves the medical and healthcare sectors in the U.S. and Canada processing over 100,000 tests per year for fungal infections. This includes antigen and antibody detection tests for coccidioides (valley fever fungus), aspergillus, histoplasmosis capsulatum, Blastomyces dermatitidis and cryptococcus.

MiraVista Diagnostics offers same-day testing, prompt response, fast shipping and direct access to the laboratory’s team of experienced infectious disease specialists that has collectively published more than 1,000 scientific research articles. Clients include large medical research hospitals, healthcare systems and universities as well as large reference labs. Contact us to discuss a fungal infection case, set up a corporate account for high volume testing or order from among MiraVista Diagnostics’ menu of diagnostic screening tests for fungal diseases.

Company News

Are You Underdiagnosing Coccidioidomycosis?

Are You Underdiagnosing Coccidioidomycosis? Capture Additional Cases with Combined Antigen and Antibody Testing. Dear Colleagues, The prevailing method for diagnosis of coccidioidomycosis is serum antibody testing by immunodiffusion (ID) with a sensitivity of 84.2% and specificity of 96.5%, but a…
READ MORE →

Test Report Updates for 2020

In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our test report format to our referral testing customers. Minor changes have been made to the layout, while critical information such as…
READ MORE →

MiraVista COVID-19 Announcement

MiraVista is open and continues to provide critical diagnostic testing despite the impact COVID-19 has had on staffing. The health and welfare of our team is of critical importance. To limit the opportunity of exposure to COVID-19 for our entire…
READ MORE →

MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC)

In compliance with the National Institutes of Health Office of Science Policy (NIH OSP), MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC) to review, approve and confirm that the company’s research involving recombinant/synthetic DNA complies with NIH guidelines….
READ MORE →

Characterization of an Uncinocarpus Reesii-expressed Recombinant Tube Precipitin Antigen of Coccidioides Posadasii for Serodiagnosis

Early and accurate diagnosis of coccidioidomycosis, also known as Valley fever, is critical for appropriate disease treatment and management. Current serodiagnosis is based on the detection of patient serum antibodies that react with tube precipitin (TP) and complement fixation (CF)…
READ MORE →

ORDER TESTS
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo